A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report

Yi Chen; Hao Zhang; Junfeng Shi; Tongshan Wang

doi:10.2147/OTT.S279004

A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report

Onco Targets Ther. 2020 Dec 3:13:12471-12476. doi: 10.2147/OTT.S279004. eCollection 2020.

Authors

Yi Chen¹, Hao Zhang², Junfeng Shi^#³, Tongshan Wang^#²

Affiliations

¹ Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing 210000, People's Republic of China.
² Department of Oncology, Jiangsu Provincial People's Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, People's Republic of China.
³ Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, People's Republic of China.

^# Contributed equally.

Abstract

We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient's tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of chemotherapy. Fortunately, the tumors dramatically shrank after one cycle of camrelizumab, an anti-programmed cell death-1 (PD-1) antibody developed by Chinese Hengrui Medicine. In conclusion, camrelizumab may be a good treatment option, especially in tumors that express PD-L1.

Keywords: PD-1; RCCEP; camrelizumab; immune checkpoint inhibitor; pulmonary pleomorphic carcinoma; reactive skin capillary endothelial cell proliferation.

Publication types

Case Reports